World Vaccine Congress Investor Panel, April 4th
“…..Mr Carthy commented that “antigen specific tolerance has the potential to deliver disease modifying therapy for  indications including autoimmune, allergies and protein drug antibody reactions. AnTolRx has demonstrated both preventative and therapeutic effects in type 1 diabetes, rheumatoid arthritis and antibodies to Factor 8 treatment.  AnTolRx plans to start early development by the end of 2018…..”